Table 3: Evaluation of hypertension guideline contents for providing comprehensive care for adult patients.
S.No |
Contents |
AHA, 2018 |
Australia, 2016 |
Canada, 2017 |
HEARTs, 2018 |
ESC/ESH, 2018 |
Ethiopia, 2016 |
1 |
Introduction to hypertension |
||||||
1.1 |
Definition of hypertension |
√ |
√ |
√ |
√ |
√ |
√ |
1.2 |
BP components |
√ |
√ |
√ |
√ |
√ |
√ |
1.3 |
Population at risk |
√ |
√ |
√ |
√ |
√ |
√ |
1.4 |
Hypertension and chronic illnesses |
√ |
√ |
√ |
√ |
√ |
√ |
2 |
Diagnosis of hypertension |
||||||
2.1 |
Methods of BP measurement |
√ |
√ |
√ |
√ |
√ |
√ |
2.2 |
True hypertension |
√ |
√ |
√ |
√ |
√ |
√ |
2.3 |
Masked hypertension |
√ |
√ |
√ |
√ |
√ |
X |
2.4 |
White coat hypertension |
√ |
√ |
√ |
√ |
√ |
X |
2.5 |
Cardiovascular risk stratification |
√ |
√ |
√ |
√ |
√ |
√ |
3 |
Cases of hypertension |
√ |
√ |
√ |
√ |
√ |
X |
3.1 |
Genetic predisposition |
√ |
√ |
√ |
√ |
√ |
X |
3.2 |
Behavioral risk factors |
√ |
√ |
√ |
√ |
√ |
X |
3.3 |
Childhood risk factors |
√ |
√ |
√ |
√ |
√ |
X |
3.4 |
Secondary cases hypertension |
√ |
√ |
√ |
√ |
√ |
X |
4 |
Management of hypertension |
||||||
4.1 |
Non-pharmacological interventions |
√ |
√ |
√ |
√ |
√ |
√ |
4.2 |
Pharmacological therapy |
√ |
√ |
√ |
√ |
√ |
√ |
4.3 |
Management of hypertension with comorbidities |
√ |
√ |
√ |
√ |
√ |
√ |
5 |
Special groups (race, ethnicity, elderly) |
√ |
√ |
√ |
√ |
√ |
X |
6 |
Other considerations |
||||||
6.1 |
Resistant hypertension |
√ |
√ |
√ |
√ |
√ |
X |
6.2 |
Hypertension crisis |
√ |
√ |
√ |
√ |
√ |
√ |
6.3 |
Hypertension and pregnancy |
√ |
√ |
√ |
√ |
√ |
X |
6.4 |
Hypertension and sexual dysfunctions |
√ |
√ |
√ |
√ |
√ |
√ |
6.5 |
Hypertension and patients undergoing surgery |
√ |
√ |
√ |
√ |
√ |
X |
7 |
Strategies to improve BP control |
||||||
7.1 |
Strategies to improve treatment Adherence |
√ |
√ |
√ |
√ |
√ |
√ |
7.2 |
Structure Team-based care for hypertension |
√ |
√ |
√ |
√ |
√ |
√ |
7.3 |
Health information technology to improve BP control |
√ |
√ |
√ |
√ |
√ |
√ |
7.4 |
Clear Care plan and Dose intensification protocol |
√ |
√ |
√ |
√ |
√ |
X |
7.5 |
Monitoring and follow-up |
√ |
√ |
√ |
√ |
√ |
√ |
7.6 |
Health Literacy |
√ |
√ |
√ |
√ |
√ |
X |
7.7 |
Access to health insurance &medications |
√ |
√ |
√ |
√ |
√ |
√ |
7.8 |
Social determinants |
√ |
√ |
X |
X |
√ |
X |
√: The guideline addresses topics; X: The topic is not included in the guideline; ESC/ESH: European Society of Cardiology and the European Society of Hypertension: ACC/AHA: American College of Cardiology/ American heart Association.